Bresecia et al. have reported that CD133-silencing substantially decreases the clonogenicity in vitro and tumorigenesis in vivo, and CD133 re-expression in CD133-silenced cells reverses these anti-tumoral effects in glioma cells [33]. This evidence concerns the gene PROM1 and glioma.